These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 16949200)

  • 1. Phosphodiesterase type 5 inhibitors: the day after.
    Hatzimouratidis K; Hatzichristou D
    Eur Urol; 2007 Jan; 51(1):75-88; discussion 89. PubMed ID: 16949200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
    Roumeguère T; Zouaoui Boudjeltia K; Hauzeur C; Schulman C; Vanhaeverbeek M; Wespes E
    BJU Int; 2009 Aug; 104(4):511-7. PubMed ID: 19239452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phosphodiesterase inhibitors: effectiveness and new applications].
    van Driel MF
    Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1613-6. PubMed ID: 16901064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors.
    Taylor J; Baldo OB; Storey A; Cartledge J; Eardley I
    BJU Int; 2009 May; 103(10):1392-5. PubMed ID: 19154494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
    Kell PD; Hvidsten K; Morant SV; Harnett JP; Bridge S
    BJU Int; 2007 Apr; 99(4):860-3. PubMed ID: 17378846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
    Doggrell S
    Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Update of PDE5 inhibitors as treatment of ED].
    Lu YN; Chen B
    Zhonghua Nan Ke Xue; 2005 Jul; 11(7):552-5. PubMed ID: 16078679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase inhibitors in Raynaud's phenomenon.
    Levien TL
    Ann Pharmacother; 2006; 40(7-8):1388-93. PubMed ID: 16835313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pills for erectile dysfunction: now there are three.
    Harv Mens Health Watch; 2004 Apr; 8(9):5-6. PubMed ID: 15100064
    [No Abstract]   [Full Text] [Related]  

  • 13. Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates.
    Chang LL; Ma M; Allmen Hv; Henderson SC; Harper K; Hornbuckle K
    Curr Med Res Opin; 2010 Jun; 26(6):1451-9. PubMed ID: 20394470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
    Ströberg P; Hedelin H; Ljunggren C
    Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase 5 inhibitors: current status and potential applications.
    Rotella DP
    Nat Rev Drug Discov; 2002 Sep; 1(9):674-82. PubMed ID: 12209148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
    Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
    BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular effects of phosphodiesterase type 5 inhibitors.
    Vlachopoulos C; Ioakeimidis N; Rokkas K; Stefanadis C
    J Sex Med; 2009 Mar; 6(3):658-74. PubMed ID: 19138362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
    Martin-Morales A; Haro JM; Beardsworth A; Bertsch J; Kontodimas S;
    Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
    Kloner RA
    Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual loss with erectile dysfunction medications.
    Wooltorton E
    CMAJ; 2006 Aug; 175(4):355. PubMed ID: 16870715
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.